Evidence map›Paper›PMID 33688260›Full record

ArticleCancer management and research2021

Prognostic Analysis of Patients with Primary Extranodal Lymphoma: A Retrospective Study.

Hanying Shen, Lingling Jiang, Linlin Nie, Xiaohui Fan, Yanqiu Xu, Lingling Yin, Linyan Xu, Jieyun Xia, Zhenyu Li, Feng Zhu and 1 more

Abstract read
In one paragraph

Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hanying ShenBlood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China.
Lingling JiangBlood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China.
Linlin NieBlood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China.
Xiaohui FanBlood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China.
Yanqiu XuBlood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China.
Lingling YinDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People's Republic of China.
Linyan XuBlood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China.
Jieyun XiaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People's Republic of China.
Zhenyu LiBlood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China.
Feng ZhuBlood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China.ORCID 0000-0002-9356-2154
Kailin XuBlood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China.ORCID 0000-0003-1375-1084

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOriginating from extranodal organs or tissues, primary extranodal lymphoma (PENL) acts in different primary sites with diverse clinical performances and PENL has remarkable geographical differences and lacks the relevant reports in each region. PATIENTS AND

methodsTwo hundred and twenty PENL patients were enrolled, and the relevant clinical and laboratory indicators were analyzed. In addition, statistical methods were applied to analyze the effects of different factors on overall survival (OS) and progression-free survival (PFS) of patients.

resultsThe three most frequent primary sites of PENL are the digestive system, head and neck, and central nervous system. The patients were classified into groups based on their risk status, resulting in low-risk, medium-low-risk, medium-high-risk, and high-risk, and their respective 3-year OS values were calculated, which showed that 121 patients (55%) were in the low-risk group and 3-year OS was 85.2% (25.9% medium-low-risk, 3-year OS 66.6%; 15% medium-high-risk, 3-year OS 61.9%; 4.09% high risk, 3-year OS 45.7%). A multivariate analysis of the Cox regression demonstrated that serum beta 2-microglobulin (β

conclusionThe correlated independent risk factors such as β

Indexed as

beta 2-microglobulinlactate dehydrogenasepathological subtypeperformance statusprimary extranodal lymphomaprognostic analysis

Identifiers

PMID33688260
PMCPMC7936719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.